關(guān)鍵詞： Illumina
2013年1月8日訊 /生物谷BIOON/ -- Illumina宣布將收購Verinata Health,，收購價包括3.5億美元和2015年以前至多1億美元的里程碑付款。
Verinata是一家非侵入性測試早期發(fā)現(xiàn)胎兒染色體異常的公司,。公司預(yù)期這件交易將造成2013年非GAAP每股盈余被稀釋0.2美元,，從2014年開始將作出正面貢獻。（生物谷Bioon.com）
英文報道：
U.S. genetic sequencing company Illumina Inc said it has agreed to buy Verinata Health Inc for $350 million plus up to $100 million in milestone payments through 2015 to expand its footprint in prenatal testing options.
Verinata Health is a provider of non-invasive tests for the early identification of fetal chromosomal abnormalities.
The deal is expected to dilute Illumina's non-GAAP earnings per share by 20 cents in 2013 before turning accretive beginning in 2014 and beyond.
Illumina said the transaction will be financed primarily with cash on hand.
The Verinata deal follows after smaller peer Complete Genomics Inc rejected Illumina's takeover bid of about $114 million in November.
Bank of America Merrill Lynch acted as financial advisor to Illumina and Covington & Burling LLP acted as legal counsel.
